Rapamycin unbalances the polarization of human macrophages to M1

Immunology

Volumn 140, Issue 2, 2013, Pages 179-190

  Mercalli, Alessia ^a   Calavita, Ines ^a   Dugnani, Erica ^a   Citro, Antonio ^a   Cantarelli, Elisa ^a   Nano, Rita ^a   Melzi, Raffaella ^a   Maffi, Paola ^a   Secchi, Antonio ^a,b   Sordi, Valeria ^a   Piemonti, Lorenzo ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Cytokines; Immunotherapeutics; Macrophage polarization; Macrophages monocytes; Rapamycin; Transplantation

Indexed keywords

CCL18 CHEMOKINE; CD206 ANTIGEN; CD209 ANTIGEN; CD86 ANTIGEN; CHEMOKINE; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR4; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; LYMPHOCYTE ANTIGEN; MONOCYTE CHEMOTACTIC PROTEIN 4; RAPAMYCIN; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BLOOD DONOR; CELL STIMULATION; CELL SURVIVAL; CELL VIABILITY; CLINICAL ARTICLE; CYTOKINE RELEASE; DRUG EFFECT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MACROPHAGE; MONOTHERAPY; NORMAL HUMAN; PANCREAS ISLET TRANSPLANTATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; POLARIZATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STEM CELL; TREATMENT DURATION;

CYTOKINES; IMMUNOTHERAPEUTICS; MACROPHAGE POLARIZATION; MACROPHAGES/MONOCYTES; RAPAMYCIN; TRANSPLANTATION;

ADULT; APOPTOSIS; CYTOKINES; DIABETES MELLITUS, TYPE 1; FEMALE; FLOW CYTOMETRY; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISLETS OF LANGERHANS TRANSPLANTATION; MACROPHAGE ACTIVATION; MACROPHAGES; MALE; MIDDLE AGED; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84883761914     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12126     Document Type: Article

References (54)

1. Vezina C, Kudelski A, Sehgal SN. Rapamycin (AY-22, 989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 1975; 28:721-6.
2. Flechner SM. Sirolimus in kidney transplantation indications and practical guidelines: de novo sirolimus-based therapy without calcineurin inhibitors. Transplantation 2009; 87:S1-6.
3. Kahan BD, Kaplan B, Lorber MI, Winkler M, Cambon N, Boger RS. RAD in de novo renal transplantation: comparison of three doses on the incidence and severity of acute rejection. Transplantation 2001; 71:1400-6.
4. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, Kneteman NM, Rajotte RV. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343:230-8.
5. Salazar A, McAlister VC, Kiberd BA, Bitter-Suermann H, Al-Kerithy MF, MacDonald AS. Sirolimus-tacrolimus combination for combined kidney-pancreas transplantation: effect on renal function. Transplant Proc 2001; 33:1038-9.
6. Trotter JF, Wachs ME, Trouillot TE, Bak T, Kugelmas M, Kam I, Everson G. Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not tacrolimus. Liver Transpl 2001; 7:401-8.
7. Snell GI, Levvey BJ, Chin W, Kotsimbos AT, Whitford H, Williams TJ, Richardson M. Rescue therapy: a role for sirolimus in lung and heart transplant recipients. Transplant Proc 2001; 33:1084-5.
8. Armand P, Gannamaneni S, Kim HT et al. Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol 2008; 26:5767-74.
9. Terada N, Lucas JJ, Szepesi A, Franklin RA, Domenico J, Gelfand EW. Rapamycin blocks cell cycle progression of activated T cells prior to events characteristic of the middle to late G1 phase of the cycle. J Cell Physiol 1993; 154:7-15.
10. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell 2000; 103:253-62.
11. Inoki K, Corradetti MN, Guan KL. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 2005; 37:19-24.
12. Thomson AW, Turnquist HR, Raimondi G. Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 2009; 9:324-37.
13. Taner T, Hackstein H, Wang Z, Morelli AE, Thomson AW. Rapamycin-treated, alloantigen-pulsed host dendritic cells induce antigen-specific T cell regulation and prolong graft survival. Am J Transplant 2005; 5:228-36.
14. Baumer W, Sulzle B, Weigt H, De Vries VC, Hecht M, Tschernig T, Kietzmann M. Cilomilast, tacrolimus and rapamycin modulate dendritic cell function in the elicitation phase of allergic contact dermatitis. Br J Dermatol 2005; 153:136-44.
15. Monti P, Mercalli A, Leone BE, Valerio DC, Allavena P, Piemonti L. Rapamycin impairs antigen uptake of human dendritic cells. Transplantation 2003; 75:137-45.
16. Woltman AM, van der Kooij SW, Coffer PJ, Offringa R, Daha MR, van Kooten C. Rapamycin specifically interferes with GM-CSF signaling in human dendritic cells, leading to apoptosis via increased p27KIP1 expression. Blood 2003; 101:1439-45.
17. Hackstein H, Taner T, Logar AJ, Thomson AW. Rapamycin inhibits macropinocytosis and mannose receptor-mediated endocytosis by bone marrow-derived dendritic cells. Blood 2002; 100:1084-7.
18. Sordi V, Bianchi G, Buracchi C et al. Differential effects of immunosuppressive drugs on chemokine receptor CCR7 in human monocyte-derived dendritic cells: selective upregulation by rapamycin. Transplantation 2006; 82:826-34.
19. Woltman AM, de Fijter JW, Kamerling SW, van Der Kooij SW, Paul LC, Daha MR, van Kooten C. Rapamycin induces apoptosis in monocyte- and CD34-derived dendritic cells but not in monocytes and macrophages. Blood 2001; 98:174-80.
20. Matsue H, Yang C, Matsue K, Edelbaum D, Mummert M, Takashima A. Contrasting impacts of immunosuppressive agents (rapamycin, FK506, cyclosporin A, and dexamethasone) on bidirectional dendritic cell-T cell interaction during antigen presentation. J Immunol 2002; 169:3555-64.
21. Cao W, Manicassamy S, Tang H, Kasturi SP, Pirani A, Murthy N, Pulendran B. Toll-like receptor-mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI(3)K-mTOR-p70S6K pathway. Nat Immunol 2008; 9:1157-64.
22. + regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol 2006; 177:8338-47.
23. + regulatory T cells. Blood 2005; 105:4743-8.
24. + regulatory T-cells. Diabetes 2008; 57:2341-7.
25. + regulatory T cells cultured with rapamycin. J Immunol 2007; 178:320-9.
26. Sauer S, Bruno L, Hertweck A et al. T cell receptor signaling controls Foxp3 expression via PI3K, akt, and mTOR. Proc Natl Acad Sci U S A 2008; 105:7797-802.
27. + cells. J Exp Med 2008; 205:565-74.
28. Mercalli A, Sordi V, Ponzoni M et al. Rapamycin induces a caspase-independent cell death in human monocytes. Am J Transplant 2006; 6:1331-41.
29. Melzi R, Maffi P, Nano R et al. Rapamycin does not adversely affect intrahepatic islet engraftment in mice and improves early islet engraftment in humans. Islets 2009; 1:42-9.
30. Weichhart T, Costantino G, Poglitsch M et al. The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity 2008; 29:565-77.
31. Spentzas T, Shappley RK, Savorgnan F, Meals E, English BK. Rapamycin augments the NMDA-mediated TNF suppression of MRSA-stimulated RAW264.7 murine macrophages. Int J Inflam 2012; 2012:542727.
32. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005; 5:953-64.
33. Mantovani A, Sica A, Locati M. Macrophage polarization comes of age. Immunity 2005; 23:344-6.
34. Weichhart T, Saemann MD. The multiple facets of mTOR in immunity. Trends Immunol 2009; 30:218-26.
35. Danner S, Sigrist S, Moreau F et al. Influence of rapamycin on rat macrophage viability and chemotaxis toward allogenic pancreatic islet supernates. Transplant Proc 2008; 40:470-2.
36. Martinez FO, Gordon S, Locati M, Mantovani A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol 2006; 177:7303-11.
37. Piemonti L, Maffi P, Monti L, Lampasona V, Perseghin G, Magistretti P, Secchi A, Bonifacio E. Beta cell function during rapamycin monotherapy in long-term type 1 diabetes. Diabetologia 2011; 54:433-9.
38. Powell JD, Delgoffe GM. The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism. Immunity 2010; 33:301-11.
39. Saemann MD, Haidinger M, Hecking M, Horl WH, Weichhart T. The multifunctional role of mTOR in innate immunity: implications for transplant immunity. Am J Transplant 2009; 9:2655-61.
40. Sugatani T, Hruska KA. Akt1/Akt2 and mammalian target of rapamycin/Bim play critical roles in osteoclast differentiation and survival, respectively, whereas akt is dispensable for cell survival in isolated osteoclast precursors. J Biol Chem 2005; 280:3583-9.
41. Glantschnig H, Fisher JE, Wesolowski G, Rodan GA, Reszka AA. M-CSF, TNFα and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase. Cell Death Differ 2003; 10:1165-77.
42. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008; 8:958-69.
43. Flechner SM, Zhou L, Derweesh I et al. The impact of sirolimus, mycophenolate mofetil, cyclosporine, azathioprine, and steroids on wound healing in 513 kidney-transplant recipients. Transplantation 2003; 76:1729-34.
44. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006; 6:729-34.
45. Dibra A, Tiroch K, Schulz S et al. Drug-eluting stents in acute myocardial infarction: updated meta-analysis of randomized trials. Clin Res Cardiol 2010; 99:345-57.
46. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002; 23:549-55.
47. Stoger JL, Gijbels MJ, van der Velden S et al. Distribution of macrophage polarization markers in human atherosclerosis. Atherosclerosis 2012; 225:461-8.
48. Oh J, Riek AE, Weng S, Petty M, Kim D, Colonna M, Cella M, Bernal-Mizrachi C. Endoplasmic reticulum stress controls M2 macrophage differentiation and foam cell formation. J Biol Chem 2012; 287:11629-41.
49. Chen W, Ma T, Shen XN, Xia XF, Xu GD, Bai XL, Liang TB. Macrophage-induced tumor angiogenesis is regulated by the TSC2-mTOR pathway. Cancer Res 2012; 72:1363-72.
50. Boruchov AM, Heller G, Veri MC, Bonvini E, Ravetch JV, Young JW. Activating and inhibitory IgG fc receptors on human DCs mediate opposing functions. J Clin Invest 2005; 115:2914-23.
51. Martinet W, Verheye S, De Meyer I, Timmermans JP, Schrijvers DM, Van Brussel I, Bult H, De Meyer GR. Everolimus triggers cytokine release by macrophages: rationale for stents eluting everolimus and a glucocorticoid. Arterioscler Thromb Vasc Biol 2012; 32:1228-35.
52. Baker AK, Wang R, Mackman N, Luyendyk JP. Rapamycin enhances LPS induction of tissue factor and tumor necrosis factor-α expression in macrophages by reducing IL-10 expression. Mol Immunol 2009; 46:2249-55.
53. Pan H, O'Brien TF, Zhang P, Zhong XP. The role of tuberous sclerosis complex 1 in regulating innate immunity. J Immunol 2012; 188:3658-66.
54. Kirsch AH, Riegelbauer V, Tagwerker A, Rudnicki M, Rosenkranz AR, Eller K. The mTOR-inhibitor rapamycin mediates proteinuria in nephrotoxic serum nephritis by activating the innate immune response. Am J Physiol Renal Physiol 2012; 303:F569-75.